Qing Lin, M.D., Ph.D., M.S.

Headshot of Qing Lin
  • Assistant Professor of Anesthesiology and Critical Care Medicine



Research Interests

Wound healing; Mast cell biology; GPCR signaling; Pulmonary hypertension; Pathological angiogenesis ...read more


Dr. Qing Lin is an Assistant Professor of Anesthesiology and Critical Care Medicine (ACCM) at the Johns Hopkins University School of Medicine. He has focused on understanding the wound-healing mechanisms in skin, eyes, and lung. His research interests include skin wound repair/regeneration, pathological ocular angiogenesis, and pulmonary arterial hypertension.

Dr. Lin received his clinical training at Shantou University Medical College in China. After receiving his M.D. degree, he had M.S. training in pathophysiology and then Ph.D. training in immunology. Afterward, he obtained a position as postdoctoral research fellow in Johns Hopkins University Department of Surgery before moving onto work as a faculty member in Department of ACCM.

Dr. Lin serves on the editorial board of Frontiers in Genetics, Frontiers in Immunology, and has been a Lead Guest Editor for the Journal of Immunology Research. He has also served as a peer reviewer for more than 30 scientific journals most of which are in the field of immunology.

He is a member of professional organizations including Wound Healing Society (WHS), North American Vascular Biology Organization (NAVBO), Pulmonary Vascular Research Institution (PVRI), and American Heart Association (AHA), etc.

...read more


  • Assistant Professor of Anesthesiology and Critical Care Medicine

Departments / Divisions



  • M.D.; Shantou Univ Med College, Shantou, Guangdong (China) (2011)
  • M.S.; Shantou Univ Med College, Shantou, Guangdong (China) (2008)
  • Ph.D.; Shantou Univ Med College, Shantou, Guangdong (China) (2011)

Additional Training

Postdoctoral Fellowship: Johns Hopkins University, Baltimore, MD / Vascular Immunology (2017)

Research & Publications

Research Summary

As an immunologist, Dr. Qing Lin has expertise in mast cell biology, GPCR signaling, wound healing and regeneration. He is especially interested in the roles of damage-associated molecular pattern (DAMP) signaling in wound inflammation. Dr. Lin's studies demonstrated for the first time that toll-like receptor (TLR)-3 activation enhances skin wound repair and the TLR3 activator poly(I:C) has potential therapeutic value for wound healing in humans. In corneal wound healing, his work found that the DAMP molecule high-mobility group box-1 (HMGB1) initiates TLR4-dependent inflammatory responses that induces pathological angiogenesis. He also investigated vascular remodeling in injured lung and found that HMGB1 signaling is critical for the development of pulmonary arterial hypertension. The long-term goal of Dr. Lin’s research is to fully elucidate roles of immune cells in abnormal tissue remodeling.

Lab Summary (Principal Investigator: Qing Lin, M.D., Ph.D.)

Our lab focuses on elucidating the immuno-regulatory mechanisms in: 1) pulmonary arterial hypertension and 2) skin wound healing.

Pulmonary arterial hypertension: We seek to understand how inflammation drives the uncontrolled proliferation of vascular smooth muscle cells and subsequently relentless vascular remodeling in the lung. By investigating roles of DAMP signaling in regulating the inflammation-to-proliferation function switch of neutrophils and macrophages, we expect to gain key insights into the contributions of these immune cells to pulmonary vascular inflammation and remodeling.

Skin wound healing: Wound therapy remains a clinical challenge. Large burns or impaired-healing diabetic ulcers require enhanced wound repair. Human scarring following trauma or surgery is another major medical problem. Addressing the complex post-injury immune response is critical to defining an effective therapy for both repair and regeneration. We are particularly interested in understanding whether and how inflammation influences the balance between fibrotic and regenerative skin wound healing.

Our overarching goal is to elucidate the wound healing mechanisms in lung and skin, and develop better strategies and novel targets for treatment of vascular inflammation-related diseases including pulmonary arterial hypertension, skin wounds, and systemic sclerosis.

Technology Expertise Keywords

Immunology; Molecular Biology; Cell Signaling

Selected Publications

View all on PubMed

Lin Q, Wang L, Lin Y, Liu X, Ren X, Wen S, Du X, Lu T, Su SY, Yang X, Huang W, Zhou S, Wen F, Su SB. Toll-like receptor 3 ligand polyinosinic:polycytidylic acid promotes wound healing in human and murine skin. J Invest Dermatol. 2012;132:2085-2092

Lin Q, Fang D, Hou X, Le Y, Fang J, Wen F, Gong W, Chen K, Wang JM, Su SB. HCV peptide (C5A), an amphipathic α-helical peptide of hepatitis virus C, is an activator of N-formyl peptide receptor in human phagocytes. J Immunol. 2011;186:2087-2094

Lin Q, Yang XP, Fang D, Ren X, Zhou H, Fang J, Liu X, Zhou S, Wen F, Yao X, Wang JM, Su SB. High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1024-1032

Lin Q, Wesson RN, Maeda H, Wang Y, Cui Z, Liu JO, Cameron AM, Gao B, Montgomery RA, Williams GM, Sun Z. Pharmacological mobilization of endogenous stem cells significantly promotes skin regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus. J Invest Dermatol. 2014;134:2458-2468

Lin Q, Fan C, Gomez-Arroyo J, Van Raemdonck K, Meuchel LW, Skinner JT, Allen D. Everett AD, Fang X, Macdonald AA, Yamaji-Kegan K, Johns RA. HIMF (hypoxia-induced mitogenic factor) signaling mediates the HMGB1 (high mobility group box 1)-dependent endothelial and smooth muscle cell cross talk in pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2019;39:2505-2519. Chosen as the "Editor's Pick"


Wound Healing via Autologous Stem Cell Mobilization
Patent # US 20160106710 A1 | 03/16/2021

Application of Toll-like receptor-3 agonist to preparation of medicines for promoting wound healing
Patent # CN101780279 | 07/12/2012

Methods of recruiting SDF-producing macrophages
Patent # US20210251954A1 | 08/19/2021

Contact for Research Inquiries

Qing Lin
720 Rutland Ave
Ross 355
Baltimore, MD 21205 map
Phone: 443-287-8247

Email me

Activities & Honors


  • Career Development Award, American Heart Association, 2022 - 2025
  • First Place Award, “Immunology and Inflammation” Category, Johns Hopkins Annual ACCM Research Conference, 2021
  • First Place Award, “Cardiopulmonary” Category, Johns Hopkins Annual ACCM Research Conference, 2020
  • Stimulating and Advancing ACCM Research (StAAR) Investigator Award, Johns Hopkins University, 2018 - 2019
  • StAAR Training Award, Johns Hopkins University, 2017 - 2018
  • Young Investigator Award, Wound Healing Society, 2015
  • Poster of Merit & Travel Award, Federation of Clinical Immunology Societies (FOCIS), 2011


  • Wound Healing Society (WHS)
  • North American Vascular Biology Organization (NAVBO)
  • American Thoracic Society (ATS)
  • American Heart Association (AHA)
  • Pulmonary Vascular Research Institution (PVRI)
  • Pulmonary Hypertension Association (PHA)

Professional Activities

  • Lead Guest Editor, Journal of Immunology Research, 2017 - 2018
  • Associate Editor, Frontiers in Genetics
  • Review Editor, Frontiers in Immunology
  • Associate Editor, Frontiers in Oncology

Videos & Media

Lectures and Presentations

  • Improved Burn Wound Healing by Pharmacological Mobilization of Endogenous Stem Cells in Mice.
    Podium presentation, Wound Healing Society (WHS) Annual Meeting, San Antonio, TX. (04/30/2015)
  • Therapeutic Effects of the Generated Antibodies Targeting Human Resistin in Pulmonary Hypertension.
    Podium presentation, American Thoracic Society (ATS) 2018 International Conference, San Diego, CA. (05/23/2018)
  • B Cells Are Regulated By RELMα In Pulmonary Hypertension.
    Podium presentation, The 64th Thomas L. Petty Aspen Lung Conference, Aspen, CO. (06/10/2022)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button